FreeStyle Libre 2 Discharge Trial

Inclusion Criteria: 1. Males and females ≥18 years of age admitted to general medicine and surgery services. 2. Known history of T2D treated with oral antidiabetic agents (sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinedione, DPP-4 inhibitors, SGLT2- inhibitors), GLP1-RAs (exenatide, liraglutide, dulaglutide, semaglutide) or insulin therapy (human regular or rapid-acting analogs or ultra-rapid analogs [ lispro, aspart, glulisine, fast acting insulin aspart, insulin lispro]), intermediate acting (NPH and premixed formulations) or long-acting basal (glargine, detemir, degludec) formulations. 3. Discharged on insulin therapy consisting of basal therapy 1) with or without bolus insulin and also 2) with or without other diabetes drugs. Exclusion Criteria: 1. Subjects admitted with a diagnosis of diabetic ketoacidosis or hyperosmolar hyperglycemic state. 2. Subjects using CGM technology prior to admission 3. Subjects with type 1 diabetes 4. Subjects not willing to receive insulin injections or test POC 4 times daily 5. Subjects discharged from the hospital on diabetes therapy that does not include basal insulin. 6. Subjects not willing to wear a CGM device 7. Pregnant women 8. Subjects with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension) and end-stage kidney disease (eGFR< 30 ml/min), dialysis, critically ill or terminal illness. 9. Subjects with history of cognitive impairment, dementia, or mental condition rendering the subject unable to understand the nature and consequences of the study. 10. Subjects expected to be readmitted to the hospital within 3 months post-discharge.